David Franklin (scientist)

David Franklin
Born1961 (age 6364)
Alma materUniversity of Rhode Island (doctoral)
Harvard Medical School (Post-doctoral)
Known forPrecedent setting stance against pharmaceutical industry fraud.
Automated decision-making
Multiple-criteria decision analysis
Renowned modern art and contemporary art collection.
AwardsDana–Farber Cancer Institute Abraham Fellowship in Pediatric Oncology
National Research Service Award
Scientific career
FieldsBiotechnology/Entrepreneurship
Evidence-based medicine
Dempster–Shafer theory
Decision theory
Complex adaptive system
InstitutionsBSX
IDXX
Parke-Davis
Doctoral advisorPaul Cohen
Other academic advisorsBarbara Bierer
Jamie Ferreira

David Franklin is an American microbiologist and former fellow of Harvard Medical School who while employed by Parke-Davis filed the 1996 whistleblower lawsuit exposing their illegal promotion of Neurontin (gabapentin) for off-label uses. Franklin's suit, filed on behalf of the citizens of the United States under the qui tam provisions of US federal and state law, uncovered illegal pharmaceutical industry practices and created new legal precedent that resulted in a cascade of criminal convictions and civil and criminal penalties against Pfizer and several other pharmaceutical companies totalling more than $7 billion. Civil cases also followed Franklin v. Parke-Davis. Insurance companies, led by Kaiser Permanente, sued Pfizer for fraud and violation of the federal Racketeer Influenced and Corrupt Organizations Act; the Kaiser case settled in April 2014 after Pfizer's appeal at the US Supreme Court was rejected. Franklin v. Pfizer also spawned more than a thousand wrongful death (suicide) suits associated with use of Neurontin. Numerous books have addressed the social, economic and healthcare implications of Dr. Franklin's stance and actions. The settlement was the first off-label promotion settlement under the False Claims Act.:194